Urinary Incontinence (Stress, Urge, Overflow)

Why Acute urinary retention is correct

• Oxybutynin is an antimuscarinic (anticholinergic) agent that reduces detrusor smooth-muscle contractility to treat overactive bladder
• In a man with benign prostatic hyperplasia, the bladder already empties against a partially obstructed outlet; blunting detrusor contraction can tip him into incomplete emptying and acute urinary retention
• This bladder-outlet-obstruction interaction is what makes retention the adverse effect of greatest concern specifically because of his BPH
• The Beers Criteria flag anticholinergic agents as potentially inappropriate in older adults, and a beta-3 agonist (mirabegron) is often preferred when BPH coexists because it lacks antimuscarinic outlet effects

Why the others are wrong

• Retrograde ejaculation — an ejaculatory adverse effect of alpha-1 blockers (most often the uroselective tamsulosin and silodosin) and a common consequence of transurethral resection of the prostate; it is not an oxybutynin effect (confused-with trap: a BPH-treatment effect, not an antimuscarinic one)
• Xerostomia and dry eyes — the most common antimuscarinic adverse effects of oxybutynin and worth counseling, but they are bothersome rather than dangerous and are not amplified by prostatic obstruction (common-but-not-BPH-specific trap)
• Orthostatic hypotension — this is a class effect of the alpha-1 blockers (e.g., tamsulosin) used to treat BPH, not of oxybutynin; it is a buzzword trap from confusing the two BPH-related drug classes
• Erectile dysfunction — a sexual adverse effect classically counseled with the 5-alpha-reductase inhibitors (finasteride, dutasteride) used for BPH, along with decreased libido; it is not the danger that prostatic obstruction amplifies when an antimuscarinic blunts detrusor contraction (confused-with trap: a 5-alpha-reductase inhibitor effect, not an outlet-obstruction risk)

Additional high-yield points

• Other antimuscarinic cautions: oxybutynin is contraindicated in uncontrolled narrow-angle glaucoma, urinary retention, and gastric retention, and anticholinergic burden can worsen cognition in older adults; trospium, a quaternary amine, crosses the blood-brain barrier poorly

Why Post-void residual measurement is correct

• This man has continuous dribbling, a weak stream, a sense of incomplete emptying, and a distended bladder, pointing to overflow incontinence from chronic urinary retention, here driven by BPH-related outlet obstruction and likely diabetic neurogenic bladder.
• Post-void residual (PVR), obtained by bladder scan or catheterization, is the key step that distinguishes overflow from other incontinence types; a PVR over 150-200 mL confirms retention and incomplete emptying.
• After urinalysis, PVR is the appropriate, low-cost, noninvasive next test in any incontinence workup where retention is suspected, especially in older adults, diabetics, and men with BPH.

Why the others are wrong

• Multichannel urodynamic studies: a more invasive functional study reserved for an unclear diagnosis, treatment failure, or pre-surgical evaluation, not the first-line test here.
• Cystoscopic bladder evaluation: indicated to evaluate hematuria or suspected bladder cancer, but this patient has a bland urinalysis and no painless hematuria, so it does not address the suspected retention.
• Pelvic floor MRI imaging study: used when a pelvic floor disorder, prolapse, or anatomic abnormality is suspected, and it does not quantify residual urine, so it is not the appropriate next step.
• Standing cough stress test — this bedside test detects stress urinary incontinence, so it is tempting in any patient who leaks; but continuous dribbling with a weak stream and a distended bladder points to overflow from retention, and watching for leakage with a cough neither confirms nor quantifies incomplete emptying.